Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0650-0013 A · 1 trial · 1 indication
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| NNC0650-0013: Subcutaneous dose | EXPERIMENTAL | Participants will receive NNC0650-0013 subcutaneously in an ascending dose manner. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo to NNC0650-0013 subcutaneously. |
| NNC0650-0013: Intravenous dose | EXPERIMENTAL | Participants will receive NNC0650-0013 in an ascending dose manner intravenously. |
| Name | Type | Description |
|---|---|---|
| NNC0650-0013 A | DRUG | NNC0650-0013 will be administered subcutaneously or intravenously. |
| Placebo | DRUG | Subcutaneous administration. |
Inclusion Criteria: * Male. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index between 24.0 and 29.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. * Considered to be otherwise healthy based on the medical history, physical examinat...
NNC0650-0013 A is an investigational small molecule being studied in healthy participants. It is being developed by Novo Nordisk A/S and is currently in Phase 1 clinical development. The drug is not approved for any indication and remains under investigation.
NNC0650-0013 A is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational small molecule.
NNC0650-0013 A is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under clinical investigation.
NNC0650-0013 A has one completed Phase 1 clinical trial, identified as NCT06284798. The study, titled 'A Research Study of a New Medicine (NNC0650-0013) in Healthy Men,' was conducted in Germany and enrolled 11 male participants aged 18 years and older.
NNC0650-0013 A is the drug name used in the clinical trial record, while the trial title refers to the medicine as NNC0650-0013. Both names refer to the same investigational small molecule being developed by Novo Nordisk A/S.